Overall rank by patents
#40,582
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView Foreign Corporation
Haemostatix Limited
USPTO PatentsView assignee record - 6 granted patents across 4 technology areas, active 2016–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
6
Total patents granted
4
CPC technology areas
18.7
Avg claims per patent
-50%
5-year filing velocity
The verdict
Haemostatix holds 6 US patents across 4 technology areas, rank #40,582 of 50,000 tracked assignees.
- #40,582
- of 50,000 US assignees by volume
- Top 62%
- by Innovation Score (31.7/100)
- 18.7
- avg claims per patent
- -50%
- filing velocity, last 5 yrs
Portfolio overview
Haemostatix Limited has been granted 6 US utility patents between 2016 and 2022, placing Haemostatix Limited at rank #40,582 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.7 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Haemostatix Limited is one of the more focused assignees in the PatentsView dataset. By volume, Haemostatix sits between H&smotorsports, Llc (6 patents, rank #40,578) and Halfen Gmbh (6 patents, rank #40,586) - the closest US assignees by grant volume. The composite Innovation Score of 31.7/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 2 grants, compared with 4 in the 2015–2019 window, a -50% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Haemostatix Limited's 18.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Haemostatix Limited against peers pursuing similar technology classes.
Who files at Haemostatix's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- H&Smotorsports
H&SMOTORSPORTS, LLC
6 patents
- H C Duke & Son
H.C. Duke & Son, LLC
6 patents
- H3alth
H3ALTH TECHNOLOGIES INC.
6 patents
- HAE Kwang
HAE KWANG CO., LTD.
6 patents
- Haier Group Techn…
HAIER GROUP TECHNIQUE R&D CENTER
6 patents
- Hainan Lingkang P…
HAINAN LINGKANG PHARMACEUTICAL CO., LTD
6 patents
- Haleon CH SARL
HALEON CH SARL
6 patents
- Halfen
HALFEN GmbH
6 patents
- Haemostatix ◀
HAEMOSTATIX LIMITED
6 patents
What this shows Haemostatix holds 6 patents at rank #40,582, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Haemostatix
By rank, the assignees closest to #40,582 in granted patent volume.
- H&smotorsports, Llc #40,578 · 6 patents
- H.c. Duke & Son, Llc #40,579 · 6 patents
- H3alth Technologies Inc. #40,580 · 6 patents
- HAE Kwang Co., Ltd. #40,581 · 6 patents
- Haier Group Technique R&D Center #40,583 · 6 patents
- Hainan Lingkang Pharmaceutical Co., Ltd #40,584 · 6 patents
- Haleon CH SARL #40,585 · 6 patents
- Halfen Gmbh #40,586 · 6 patents
Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)
Other assignees with the most granted patents in Haemostatix's primary technology class.
- The Regents Of The University Of California 1,387 in class
- Novartis Ag 1,071 in class
- Merck Sharp & Dohme Llc 889 in class
- Bristol-myers Squibb Company 879 in class
- Genentech, Inc. 789 in class
- The Board Of Regents Of The University Of Texas System 744 in class
- Hoffmann-la Roche Inc. 722 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 721 in class
Haemostatix's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
32 Top 62% higher than 38% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 1 | 16.7% |
| 2017 | 2 | 33.3% |
| 2018 | 1 | 16.7% |
| 2021 | 1 | 16.7% |
| 2022 | 1 | 16.7% |
Which technologies does Haemostatix Limited patent most?
Top 4 of 4 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Specialized
Claim Depth Standard
Velocity Declining
Frequently Asked Questions
How many patents does Haemostatix Limited hold?
Haemostatix Limited holds 6 US granted patents filed between 2016 and 2022, spanning 4 technology areas.
What is Haemostatix Limited's Innovation Score?
Haemostatix Limited has an Innovation Score of 31.7 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Haemostatix Limited focus on?
Haemostatix Limited's top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 6 patents. The company has filed patents in 4 CPC subclasses total.
Is Haemostatix Limited's patent filing rate increasing or decreasing?
Haemostatix Limited's recent filing velocity is -50% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Haemostatix Limited's patents?
Haemostatix Limited's patents average 18.7 claims each. This falls within the standard range, providing solid legal coverage.
How is the Haemostatix Limited patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Haemostatix's 6 grants land it in the top 62% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Haemostatix ranks #40,582 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61P - see who else leads that technology area. A61P leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.